NASDAQ:PBYI - Puma Biotechnology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$34.27 +0.42 (+1.24 %)
(As of 04/23/2019 11:49 AM ET)
Previous Close$33.85
Today's Range$33.64 - $34.58
52-Week Range$17.60 - $68.90
Volume8,401 shs
Average Volume1.04 million shs
Market Capitalization$1.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.7
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$251 million
Book Value$0.90 per share

Profitability

Net Income$-113,570,000.00

Miscellaneous

Employees272
Market Cap$1.32 billion
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable

Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NASDAQ:PBYI) issued its earnings results on Thursday, February, 28th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.92) by $0.12. The biopharmaceutical company had revenue of $71.10 million for the quarter, compared to the consensus estimate of $53.46 million. Puma Biotechnology had a negative return on equity of 258.02% and a negative net margin of 45.22%. View Puma Biotechnology's Earnings History.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Puma Biotechnology.

What price target have analysts set for PBYI?

12 brokerages have issued 12-month target prices for Puma Biotechnology's stock. Their forecasts range from $21.00 to $106.00. On average, they anticipate Puma Biotechnology's share price to reach $52.20 in the next twelve months. This suggests a possible upside of 52.3% from the stock's current price. View Analyst Price Targets for Puma Biotechnology.

What is the consensus analysts' recommendation for Puma Biotechnology?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Puma Biotechnology.

What are Wall Street analysts saying about Puma Biotechnology stock?

Here are some recent quotes from research analysts about Puma Biotechnology stock:
  • 1. Cowen Inc analysts commented, "Cidara reported 4Q18 financial results yesterday and we spoke w/ mgmt for an update. Phase 3 RESTORE trial of rezafungin in Candidemia/ Invasive Candidiasis was initiated last yr and enrollment rate is reportedly in line w/ expectations. Mgmt guiding for top-line results in mid-2020 (unch). Discussions are still ongoing w/ both EMA and FDA around Phase 3 RESPECT trial in prophylaxis. Mgmt nevertheless guiding for initiation in 1H19. Top-line results from Phase 2 STRIVE B trial likely mid-2019. We assume safety/ efficacy profile similar to STRIVE A. Company reported impressive progress w/ a Cloudbreak Influenza candidate last yr and expects to nominate a development candidate 1Q19. BUY. We acknowledge cash constraints, but believe stock does not adequately reflect value of pipeline." (3/1/2019)
  • 2. Cantor Fitzgerald analysts commented, ": Reiterate OW rating; increasing PT to $57/share. Nerlynx roared in 4Q, and 2019 guidance beats expectations. US Nerlynx sales were $61M vs. $53M consensus. Although gross to net was lower in 4Q, we think that 4Q represents a solid beat, and we saw growth in bottles of 12%. In addition, the company’s 2019 US guidance of $255-280M announced on the call exceeded expectations of $238M. Lastly, the company had its first cash flow positive quarter at ~$8M. Shares have recovered by 59% from their early November lows, but we think that there remains upside to shares from Nerlynx growth. We spoke to management post call and we highlight some of our key takes below." (2/28/2019)
  • 3. According to Zacks Investment Research, "Puma Biotech's only marketed drug, Nerlynx, was approved for early stage HER2-positive breast cancer. The drug has improved sales steadily since launch in July 2017. Nerlynx was also approved in the EU during September, which can generate additional sales in the future quarters. However, sale of the drug in the third quarter of 2018 fell below expectations due to higher patient discontinuation. Meanwhile, several additional studies on Nerlynx targeting different types of breast cancer patient populations and in earlier-line settings are currently underway. The drug’s label expansion will allow it to treat and access an expanded patient population. Shares have underperformed the industry in 2018. Due to the lack of a strong pipeline, the company is totally dependent on Nerlynx for growth. Hence, any kind of regulatory setback for Nerlynx could affect the company’s growth prospects." (1/3/2019)

Has Puma Biotechnology been receiving favorable news coverage?

News stories about PBYI stock have been trending positive on Tuesday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Puma Biotechnology earned a news impact score of 2.7 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.

Who are some of Puma Biotechnology's key competitors?

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (Arry), Freeport-McMoRan (FCX) and Celgene (CELG).

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the folowing people:
  • Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 49)
  • Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 62)
  • Mr. Steven Lo, Chief Commercial Officer (Age 52)
  • Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 71)
  • Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 50)

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a number of of institutional and retail investors. Top institutional investors include First Manhattan Co. (1.11%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Institutional Ownership Trends for Puma Biotechnology.

Which institutional investors are selling Puma Biotechnology stock?

PBYI stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co.. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $34.28.

How big of a company is Puma Biotechnology?

Puma Biotechnology has a market capitalization of $1.32 billion and generates $251 million in revenue each year. The biopharmaceutical company earns $-113,570,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe.

What is Puma Biotechnology's official website?

The official website for Puma Biotechnology is http://www.pumabiotechnology.com.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]


MarketBeat Community Rating for Puma Biotechnology (NASDAQ PBYI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  421 (Vote Outperform)
Underperform Votes:  385 (Vote Underperform)
Total Votes:  806
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel